San Diego gets telemedicine for its tiniest patients

Tri-City Medical Center of Oceanside, Calif., is teaming with UC San Diego Medical Center to offer telemedicine services for premature babies in greater San Diego.

Under the program, neonatal specialists from the two hospitals, which are separated by about 38 miles, will collaborate to diagnose and treat tough cases. They will use real-time, two-way audio/video connections to reduce the need for Tri-City's 20-bassinet neonatal intensive care unit to transport patients to 49-bassinet UC San Diego.

The plan is for physicians, nurses and other healthcare professionals to collaborate for optimal outcomes as they learn various diagnoses firsthand by participating in live video streaming.

UC San Diego’s enterprise-wide telemedicine program has been up and running since 2009. The institution said a key feature of the program is that its “core workflow, checklists and deployment strategies can be integrated” into the clinical strategic plan of most any department at the medical center.

“When a complex case arises, our partners at Tri-City can request a consult and can contact us using the camera system,” said Brett C. Meyer, MD, medical director of telemedicine for UC San Diego. “Our specialists can not only contribute to the care, but with telemedicine they are, in essence, virtually present in the room with the patient to render assistance.”

The state of California has awarded funding to UC San Diego to cover the costs of telemedicine equipment and maintenance, while a grant from the Tri-City Hospital Foundation will pay for the credentialing of UC San Diego physicians participating in the program.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.